IDEXX Laboratories, Inc.
Rank #20Capital ReturnIDXX · Nasdaq · Healthcare
IDEXX Laboratories, Inc. (IDXX) — Rank #20 by gross profitability (GP/assets 0.77) · ROE 65.7% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0000874716 · all metrics point-in-time as of the filing date.
About
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Show moreShow less
It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc.
was incorporated in 1983 and is headquartered in Westbrook, Maine.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- idexx.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilitystable
- Net cashimproving
- Operating marginstable
- Return on equitydeteriorating
- Share count (dilution)improving
Red flags: fcf_ni_divergence_unfavorable — rating capped at Stable
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-20 | 2024-12-31filed 2025-02-21 | 2023-12-31filed 2024-02-22 | 2022-12-31filed 2023-02-16 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 4,303.7 | 3,897.5 | 3,661.0 | 3,367.3 |
| Revenue growth (YoY) | 10.4% | 6.5% | 8.7% | 4.7% |
| Gross profit | 2,659.6 | 2,378.9 | 2,190.0 | 2,004.3 |
| Gross margin | 61.8% | 61.0% | 59.8% | 59.5% |
| Net income | 1,059.5 | 887.9 | 845.0 | 679.1 |
| Net margin | 24.6% | 22.8% | 23.1% | 20.2% |
| EPS (diluted) | $13.08 | $10.67 | $10.06 | $8.03 |
| EPS growth (YoY) | 22.6% | 6.1% | 25.3% | — |
| Cash flow | ||||
| Operating cash flow | 1,181.8 | 929.0 | 906.5 | 543.0 |
| Capital expenditures | 124.7 | 120.9 | 133.6 | 148.8 |
| Free cash flow | 1,057.1 | 808.1 | 772.9 | 394.1 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?